Science Exchange, a marketplace for outsourced R&Dk, has partnered with Reveal Biosciences to offer on-demand access to artificial intelligence (AI)-based pathology services worldwide.
Reveal Biosciences is a San Diego-based company that’s leading the next generation of quantitative histopathology, combining the latest artificial intelligence (AI) techniques with high-quality histology, immunohistochemistry (IHC) and in situ hybridization (ISH) to generate enhanced data from tissue samples.
Reveal’s AI-based tissue analysis utilizes trained pathology models to recognize disease patterns in whole slide digital images. This service can be applied to tumor profiling, quantitative immunohistochemistry, NASH, toxicology and quantitative multiplexing. On top of that, Reveal is generating disease-specific AI-based models as pathology decision support tools to accelerate clinical trials for the benefit of patients.
Reveal Biosciences CEO and founder Claire Weston said: “We are delighted to join forces with Science Exchange,” said Claire Weston, Ph.D., Founder and CEO of Reveal Biosciences.
“I am confident that our unique application of artificial intelligence to pathology will benefit Science Exchange’s life sciences community.”
Science Exchange co-founder and CEO Elizabeth Iorns said: “The use of AI-based tools in pathology is expected to increase significantly over time in both drug discovery and patient diagnostics as it is more cost-effective, accurate, reproducible and scalable.
“Reveal Biosciences is the leader in employing an AI-based approach in the pathology space, and we are thrilled to team up with them.”
Science Exchange is the world’s leading marketplace for outsourced R&D™, providing large R&D organizations with the fastest path from discovery through development and commercialization.
Source: Company Press Release